Michelle Levine

Principal

2024 - Current

• VC investor, focused on private biotech companies in the therapeutics/drug development space • Conducted due diligences that resulted in investments in: -Carisma Therapeutics, a first-in-class cell therapy platform company -Immunitas Therapeutics, an omics-based platform company identifying novel targets in immuno-oncology -Carbon Bio, a novel, non-AAV viral vector gene therapy company -Ensoma, an in vivo cell and gene therapy platform company -Recode Therapeutics, a next-generation, clinical-stage LNP platform company

Senior Associate

2021 - 2024

Associate

2020 - 2021

Consultant

2019 - 2020

• Strategy consulting for executives and product team leads in biopharma and healthcare industry • Select engagements include: -Evaluation of commercial opportunity for an academic client with a discovery-stage gene therapy platform -Recommendation of a lead program for a biotech startup company, based on an assessment of the client’s preclinical platform technology and a 5-year projection of the cell therapy landscape within oncology

Business Analyst Intern

2019 - 2019

• Conducted due diligence on an investment opportunity in the CNS space • Assessed potential opportunities in the synthetic biology space • Assisted in deal flow of life sciences startups

Ph.D. Graduate

2013 - 2019

Laboratory of Dr. Andrew Holland, Ph.D. • Determined that supernumerary centrosomes play a causative role in tumorigenesis (Levine et al., Dev Cell, 2017) • Discovered that the deuterosome, a structure previously thought to be essential for motile cilia formation, was dispensable (Mercey and Levine, et al., Nature Cell Bio, 2019) • Studied the role of extra centrosomes in polycystic kidney disease

Intern Analyst

2017 - 2018

• Performed scientific due diligence an animal health startup company • Assisted in market and competitive analysis in preparation of Series A fundraising for a NewCo • Worked on biotech company creation with a cross-disciplinary team

Case Competition Team Captain

2018 - 2018

• Led a team of 4 in the JHGCC biotechnology case competition • Identified a new consumer target and product offering for a stem cell banking company that was projected to increase profit by $20 million within 5 years

Pro-bono Consultant

2018 - 2018

• Worked with a team of 7 to decide future market opportunities for an emerging biotech. company that produces melanin, a biopolymer that can be used for diverse biomedical applications • Performed competitive analysis to address potential risks/threats in the melanin space

Research Technician

2009 - 2013

Laboratory of Dr. Nancy Berliner, M.D. • Investigated the impact of the thrombopoietin receptor agonist, eltrombopag, on platelet production utilizing multiple myeloma patient samples • Interrogated the specificity and efficacy of a JAK2 inhibitor in suppressing the proliferation of HSCs isolated from Polycythemia vera patients • Characterized the therapeutic benefit of vitamin D on inflammation-induced suppression of red blood cell production, which resulted in funding to study the role of vitamin D in patients with anemia of inflammation • Defined a novel interaction between a transcriptional and translational regulatory factor in myelodysplastic syndrome